- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1910EUR$2,000USD£1,597GBP
- Clinical Trials
- August 2024
- 529 Pages
Global
From €3295EUR$3,450USD£2,755GBP
- Report
- May 2024
- 140 Pages
Global
From €6207EUR$6,499USD£5,190GBP
- Report
- June 2024
- 200 Pages
Global
From €7593EUR$7,950USD£6,349GBP
- Report
- January 2022
- 60 Pages
Global
From €3772EUR$3,950USD£3,155GBP
Delirium is a type of mental disorder characterized by confusion, disorientation, and disturbances in attention, thought, and behavior. It is a common complication of critical illness and is associated with increased mortality and morbidity. Delirium is a major public health problem, particularly in elderly patients. The delirium drug market is a subset of the larger Central Nervous System (CNS) drug market. CNS drugs are used to treat a variety of neurological and psychiatric disorders, including delirium. The delirium drug market is expected to grow due to the increasing prevalence of delirium in elderly patients, as well as the development of new drugs to treat the condition.
Some of the major companies in the delirium drug market include Pfizer, Merck, Johnson & Johnson, Novartis, and Eli Lilly. These companies are involved in the development and marketing of drugs for the treatment of delirium. Show Less Read more